Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Remain Skeptical

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Synta provided one-year follow-up data for its Phase IIb/III trial testing ganetespib in NSCLC and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.

You may also be interested in...

Synta’s Ganetespib Could Break The Hsp90i Curse

If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.

Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market

With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.

Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer

Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts